| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Castle Biosciences, Inc.$20.52
+0.06 (+0.29%)
C 41Pipeline Score Diagnostics · Commercial
Market Cap
611.15 M
EPS
-0.43
P/E Ratio
-
Value Trade
10.52 M
SEC Financials
Q1 2026Dilution Risk
Revenue
83.68 M
R&D Expenses
14.43 M
Operating CF
-22.13 M
Total Assets
547.80 M
Total Liabilities
86.39 M
Equity
461.42 M
D/E Ratio
12,345
7.81 %
Week
-18.49 %
1 Month
-36.25 %
3 Month
-43.56 %
6 Month
-65.98 %
5 Year
0.75 %
All Time
Cash Data
Cash Position
261.69 M
Monthly Burn
7.38 M
Runway
34.4 mo
Burn Trend
SEC Filing
May 6, 2026
Overview
Volume
47.62 K
52 Week Range
14.59 - 44.28
% held by Insiders
2.66 %
% held by Institutions
91.45 %
Enterprise Value
386.19 M
Total Shares
30.28 M
Short %
5.24 %
Float Shares
28.32 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
C41
Pipeline Score $484M
Pipeline ValueValuation Signal
6
Drugs Scored0.8x
rNPV / MCap Top 61%
Micro Cap (rank 354 of 905)
Percentile RankCastle Biosciences, Inc. carries a moderate pipeline score (41/100), with $1.2B risk-adjusted pipeline value, led by Berberine in Schizophrenia (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Berberine Small molecule | Schizophrenia | Phase 2 | NCT02983188 | 43% | $377M | COMPLETED | 113 | - | - | Jan 4, 2021 | - | Jan 22, 2021 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in CSTL
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
CSTL
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
CSTL
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
CSTL
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
CSTL Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
CSTL Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
CSTLCastle Biosciences' TissueCypher® Test Surpasses 100,000 Orders, Advancing Precision Risk Assessment for Patients with Barrett's Esophagus
Castle Biosciences announced that its TissueCypher Barrett's Esophagus Test has surpassed 100,000 clinical test orders. This AI-derived test predicts the five-year risk of progression from Barrett's esophagus to high-grade dysplasia or esophageal adenocarcinoma, aiding clinicians in personalizing patient management. The milestone reflects increasing adoption and positive patient feedback.
Read more →CSTLFirst Patient Enrolled in New Study Assessing early prediction of flares in Atopic Dermatitis by Castle Biosciences in Collaboration with SciBase
SciBase has enrolled the first patient in a clinical study aimed at predicting flare-ups in atopic dermatitis. The DETECT-AD study will utilize Electrical Impedance Spectroscopy to identify early signs of flares, shifting from reactive to proactive treatment approaches. This initiative seeks to improve patient quality of life and reduce the unpredictability of flare-ups.
Read more →CSTLCastle Biosciences to Present at the 2026 Jefferies Global Healthcare Conference
Castle Biosciences, Inc. will present at the 2026 Jefferies Global Healthcare Conference on June 3, 2026. The presentation will provide an overview of the company's innovative diagnostics aimed at improving patient care. A live audio webcast will be available, along with a replay post-event. The company specializes in dermatologic and gastroenterological disease management.
Read more →CSTLCastle Biosciences' AdvanceAD-Tx™ Test Receives 2026 MedTech Breakthrough Award for Genomics Innovation
Castle Biosciences has been awarded the 'Genomics Innovation Award' for its AdvanceAD-Tx test, which aids in treatment decisions for moderate-to-severe atopic dermatitis. This non-invasive test measures gene expression to guide therapy selection, resulting in improved patient outcomes. The award highlights Castle's ongoing commitment to innovation in healthcare technology.
Read more →CSTLCastle Biosciences to Release First Quarter 2026 Financial Results and Host Webcast on Wednesday, May 6, 2026
Castle Biosciences, Inc. announced it will release its financial results for Q1 2026 on May 6, 2026. The results will be shared after market close, followed by a webcast at 4:30 p.m. ET. This event will include a Q&A session, promoting engagement with investors and stakeholders.
Read more →CSTLCastle Biosciences Earns 2026 USA TODAY Top Workplaces Award for Fifth Consecutive Year
Castle Biosciences has been awarded the 2026 USA TODAY Top Workplaces Award for the fifth consecutive year, highlighting its commitment to a people-first culture. The award is based on employee feedback and reflects the company's dedication to improving patient care. CEO Derek Maetzold emphasized the importance of valuing and empowering team members.
Read more →CSTLCastle Biosciences’ DecisionDx®-Melanoma Test Significantly Improves Risk Prediction Within AJCC Stages to Support Personalized, Risk-Aligned Management of Cutaneous Melanoma, Data to Be Presented at AAD 2026
Castle Biosciences will present data at the AAD 2026 showing that its DecisionDx-Melanoma test enhances risk stratification for cutaneous melanoma patients. The test identifies significant differences in mortality risk within AJCC stages, allowing for more personalized management. This could lead to better care for high-risk patients while reducing unnecessary interventions for those at lower risk.
Read more →CSTLDecisionDx®-Melanoma’s i31-SLNB: Report from the Largest Prospective Multicenter Study to Date Confirms 2.6% Nodal Positivity in Patients Predicted to Have Less Than 5% Risk
Recent findings from the largest prospective multicenter study on DecisionDx-Melanoma's i31-SLNB test reveal a 2.6% actual sentinel lymph node (SLN) positivity rate in patients predicted to have less than 5% risk. This supports the test's effectiveness in identifying low-risk patients who may safely avoid unnecessary SLNB procedures. The study highlights the test's role in enhancing decision-making for melanoma management.
Read more →CSTLCastle Biosciences to Present Data at SSO 2026 on DecisionDx®-Melanoma’s i31-SLNB, Identifying T1b–T2a Melanoma Patients Who May Safely Avoid SLNB
Castle Biosciences will present new data on the DecisionDx-Melanoma's i31-SLNB test at the SSO 2026 Annual Meeting. This test helps identify T1b–T2a melanoma patients who may safely avoid sentinel lymph node biopsy. The data supports the test's role in guiding risk-aligned management decisions consistent with established guidelines.
Read more →CSTLCastle Biosciences Announces Grand Opening of New Corporate Headquarters in Friendswood, Texas
Castle Biosciences has announced the grand opening of its new corporate headquarters in Friendswood, Texas, scheduled for March 24, 2026. The facility aims to foster collaboration and innovation among employees while supporting the company's growth in molecular diagnostics. Local officials will attend the event, highlighting the company's commitment to the community. The new campus features modern workspaces and sustainable design elements.
Read more →CSTLCastle Biosciences to Release Fourth Quarter and Full-Year 2025 Financial Results and Host Conference Call on Thursday, Feb. 26, 2026
Castle Biosciences, Inc. will announce its fourth quarter and full-year 2025 financial results on February 26, 2026. The results will be shared after market close, followed by a conference call at 4:30 p.m. ET. Investors can access the call via phone or webcast, with a Q&A session included.
Read more →CSTLCastle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - December 19, 2025
Castle Biosciences announced the granting of restricted stock units (RSUs) to 83 employees as an inducement for their employment. The RSUs, totaling 139,494 shares, will vest over four years, aligning employee retention with company growth. This initiative is part of the company's 2022 Inducement Plan, adhering to Nasdaq Listing Rule 5635(c)(4).
Read more →CSTLCastle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Castle Biosciences, Inc. has granted restricted stock units (RSUs) to 83 employees as part of its 2022 Inducement Plan, in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs, covering 139,494 shares, will vest over four years, incentivizing employee retention. This initiative underscores the company's commitment to enhancing its workforce while focusing on innovative diagnostic solutions.
Read more →CSTLLandmark Study Shows Combination of Castle Biosciences' DecisionDx®-UM and PRAME Outperforms Gene Mutation Analysis in Predicting Survival Outcomes in Uveal Melanoma
Castle Biosciences announced results from a landmark study showing that the combination of DecisionDx-UM and PRAME gene expression analysis outperforms traditional gene mutation analysis in predicting survival outcomes for uveal melanoma patients. This study, the largest of its kind, highlights the importance of precise risk stratification in guiding treatment decisions. The findings support the use of these tests in clinical practice for better patient management.
Read more →CSTLCastle Biosciences to Present at the Piper Sandler 37th Annual Healthcare Conference
Castle Biosciences, a diagnostics company, will present at the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025. The presentation will provide an overview of the company's innovative tests aimed at improving patient care. A live audio webcast will be available for those unable to attend in person.
Read more →CSTLCastle Biosciences Reports Third Quarter 2025 Results
Castle Biosciences reported strong financial results for Q3 2025, achieving $83 million in revenue and a 67% increase in non-dermatologic revenue compared to the previous year. The company raised its full-year revenue guidance to $327-335 million, highlighting the success of its core tests, including DecisionDx-Melanoma and TissueCypher. Additionally, the launch of AdvanceAD-Tx aims to improve treatment decisions for patients with moderate-to-severe atopic dermatitis.
Read more →CSTLCastle Biosciences Launches AdvanceAD-Tx™ to Help Guide Systemic Treatment Decision Making in Patients with Moderate-to-Severe Atopic Dermatitis
Castle Biosciences has launched AdvanceAD-Tx, a gene expression profile test aimed at guiding systemic treatment decisions for patients aged 12 and older with moderate-to-severe atopic dermatitis. The test identifies patients likely to benefit from JAK inhibitors, showing improved outcomes compared to traditional therapies. This launch reflects the company's strategy to address unmet needs in dermatology and is expected to tap into a significant market opportunity.
Read more →CSTLCastle Biosciences to Participate in Upcoming Investor Conferences
Castle Biosciences, Inc. announced its participation in the Stephens 27th Annual Investment Conference on November 19, 2025, where the executive management will present a company overview. Additionally, the company will hold one-on-one meetings during the Jefferies Global Healthcare Conference from November 18-20, 2025. The firm focuses on innovative diagnostic tests for various health conditions.
Read more →CSTLNew Data at American College of Gastroenterology Annual Meeting Show TissueCypher® Provides Actionable Risk Insights that Influence Clinical Management and Prompt Risk-Aligned Intervention in Barrett’s Esophagus
Castle Biosciences presented new data at the ACG 2025 Annual Meeting, showcasing its TissueCypher Barrett's Esophagus test. This test offers risk insights that extend beyond traditional pathology, allowing for personalized clinical management and timely interventions for patients at higher risk of esophageal cancer. The findings emphasize the importance of individualized patient care in managing Barrett's esophagus.
Read more →CSTLNew Analysis of 13,560 Patients Demonstrates DecisionDx®-Melanoma Stratifies Risk Across Histological Subtypes; Findings to be Presented at Fall Clinical Dermatology Conference
Castle Biosciences announced the presentation of new data on its DecisionDx-Melanoma test at the Fall Clinical Dermatology Conference. The study, involving 13,560 patients, confirms the test's ability to stratify melanoma risk across different histological subtypes. This finding reinforces the test's clinical value in guiding patient management and treatment decisions.
Read more →CSTLCastle Biosciences to Release Third Quarter 2025 Financial Results and Host Conference Call on Monday, Nov. 3, 2025
Castle Biosciences, Inc. will announce its third quarter financial results on November 3, 2025. Following the release, management will host a conference call and webcast at 4:30 p.m. ET to discuss the results. The company is focused on innovative tests that improve patient care and has a diverse portfolio in diagnostics.
Read more →CSTLCastle Biosciences’ Founder, President and CEO Derek Maetzold Honored with the CEO of the Year Award by The CEO Magazine
Derek Maetzold, founder and CEO of Castle Biosciences, has been awarded CEO of the Year by The CEO Magazine. This recognition highlights his innovative leadership and commitment to patient care, which has transformed Castle from a startup into a leading diagnostics company. Under his guidance, the company has fostered a strong workplace culture and developed a portfolio of tests for critical health challenges.
Read more →CSTLCastle Biosciences Honored with a Greater Pittsburgh Top Workplaces 2025 Award
Castle Biosciences has been awarded the Greater Pittsburgh Top Workplace for 2025, based on anonymous employee feedback. This recognition reflects the company's strong workplace culture, which prioritizes employee satisfaction and engagement. CEO Derek Maetzold attributes this honor to the dedication of their employees in enhancing patient care. Castle has received multiple accolades this year, showcasing its commitment to a positive work environment.
Read more →CSTLCastle Biosciences Named One of Newsweek’s America’s Greatest Companies 2025
Castle Biosciences has been recognized in Newsweek's inaugural list of America's Greatest Companies for 2025. The company was honored for its strong performance in financial strength, workforce dedication, innovation, and commitment to sustainability. CEO Derek Maetzold emphasized the company's dedication to patient care and innovation. This recognition reflects the company's efforts to transform disease management.
Read more →Competitive Position
How CSTL ranks across every disease it competes inCompetitive Position is a premium feature
See how CSTL ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial